Garcia-Martinez J, Bakker B, Schukken KM, Simon JE, Foijer F. Aneuploidy in stem cells. World J Stem Cells 2016; 8(6): 216-222 [PMID: 27354891 DOI: 10.4252/wjsc.v8.i6.216]
Corresponding Author of This Article
Floris Foijer, PhD, European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, A. Deusinglaan 1, NL-9713 AV Groningen, The Netherlands. f.foijer@umcg.nl
Research Domain of This Article
Cell Biology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Jun 26, 2016; 8(6): 216-222 Published online Jun 26, 2016. doi: 10.4252/wjsc.v8.i6.216
Aneuploidy in stem cells
Jorge Garcia-Martinez, Bjorn Bakker, Klaske M Schukken, Judith E Simon, Floris Foijer
Jorge Garcia-Martinez, Bjorn Bakker, Klaske M Schukken, Judith E Simon, Floris Foijer, European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, NL-9713 AV Groningen, The Netherlands
Author contributions: Garcia-Martinez J and Bakker B contributed equally; all authors contributed to this paper.
Supported by The Pediatric Oncology Foundation Groningen (SKOG; http://www.kinderoncologiegroningen.nl); European Union (Marie Curie Innovative Training Network PloidyNet, http://aneuploidy.nl); and Dutch Cancer Society (http://www.kwf.nl grant# 2012-RUG-5549) for funding.
Conflict-of-interest statement: Authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Floris Foijer, PhD, European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, A. Deusinglaan 1, NL-9713 AV Groningen, The Netherlands. f.foijer@umcg.nl
Telephone: +31-50-3617300 Fax: +31-50-3617310
Received: November 17, 2015 Peer-review started: November 23, 2015 First decision: January 18, 2016 Revised: February 18, 2016 Accepted: March 17, 2016 Article in press: March 18, 2016 Published online: June 26, 2016
Abstract
Stem cells hold enormous promise for regenerative medicine as well as for engineering of model systems to study diseases and develop new drugs. The discovery of protocols that allow for generating induced pluripotent stem cells (IPSCs) from somatic cells has brought this promise steps closer to reality. However, as somatic cells might have accumulated various chromosomal abnormalities, including aneuploidies throughout their lives, the resulting IPSCs might no longer carry the perfect blueprint for the tissue to be generated, or worse, become at risk of adopting a malignant fate. In this review, we discuss the contribution of aneuploidy to healthy tissues and how aneuploidy can lead to disease. Furthermore, we review the differences between how somatic cells and stem cells respond to aneuploidy.
Core tip: Stem cells hold great therapeutic promise for regenerative medicine, especially with new protocols that can create induced pluripotent stem cells from terminally differentiated cells. However, somatic cells and stem cells cope differently with genomic instability. Therefore, it will be of the utmost importance to assess genomic integrity when preparing stem cell cultures for future therapy.
